Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2021-08-27
- Target Recruit Count
- 427
- Registration Number
- NCT04679064
- Locations
- 🇮🇹
Istituto Tumori della Romagna IRST IRCCS, Meldola, Italy
🇮🇹Azienda Ospedaliera Spedali Civili, Brescia, Italy
🇮🇹IEO-Istituto Europeo di Oncologia, Milan, Italy
Cabozantinib With Topotecan-Cyclophosphamide
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04661852
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Prospective International Multicenter Clinical Trial for Eyes With Relapsed Retinoblastoma
- First Posted Date
- 2020-07-02
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Prof. Beck Popovic Maja
- Target Recruit Count
- 2
- Registration Number
- NCT04455139
- Locations
- 🇨🇭
CHUV Lausanne University Hospital, Lausanne, Switzerland
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Bone ScanDrug: CarboplatinProcedure: Computed TomographyDrug: CyclophosphamideDrug: DoxorubicinDrug: EtoposideDrug: IfosfamideDrug: IrinotecanProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyRadiation: Radiation TherapyProcedure: Surgical ProcedureProcedure: Transabdominal UltrasoundDrug: TopotecanDrug: VincristineProcedure: X-Ray Imaging
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT04322318
- Locations
- 🇺🇸
Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States
9-ING-41 in Pediatric Patients with Refractory Malignancies.
- Conditions
- Interventions
- First Posted Date
- 2020-01-23
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Actuate Therapeutics Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04239092
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-30
- Last Posted Date
- 2019-12-30
- Target Recruit Count
- 386
- Registration Number
- NCT04213937
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- ImmunoGen, Inc.
- Target Recruit Count
- 453
- Registration Number
- NCT04209855
- Locations
- 🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-26
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 71
- Registration Number
- NCT04106219
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇧🇪UZ Gent, Gent, Oost-Vlaanderen, Belgium
🇯🇵National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 184
- Registration Number
- NCT04073550
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT04029688
- Locations
- 🇺🇸
Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States
🇺🇸Lucile Packard Children's Hospital at Stanford University; Thoracic Oncology, Palo Alto, California, United States
🇺🇸Arnold Palmer Hosp-Children, Orlando, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.